Global HIV/HBV/HCV Test Kits Market - 2022-2029

Market Overview

The global HIV/HBV/HCV test kits market size was valued US$ YY million in 2021 and is expected to reach US$ XX million by 2029, growing at a CAGR of 6.8 % during the forecast period (2022-2029).

HIV/HBV/HCV test is a test of qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and HCV in human serum, plasma, or whole blood.

Market Dynamics

Innovations in the HIV/HBV/HCV rapid test kits is expected to drive market growth.

In sub-Saharan Africa, where co-infection rates are high, the burden of HIV, HBV, and HCV infections continues to be disproportionately high. High analytical performance multiplex fast diagnostic procedures for HIV, HBV, and HCV serological testing may enhance the cascade of screening and result in more cost-effective linkage to care. Such a testing approach may be especially helpful for high-risk populations challenging to reach and may also boost the impact of self-testing on public health. For instance, The prototype finger-stick whole-blood Triplex HIV/HCV/HBsAg self-test may offer a quick, affordable, tool-free, and user-friendly method for identifying HIV, HBV, and HCV infections. It might be especially appropriate for improving the screening of three endemic viral illnesses closely related in sub-Saharan Africa. These options could increase screening efforts, lowering the future cost of diseases caused by undiagnosed HIV, HBV, or HCV infections and assisting with efforts to treat these infections and potentially eradicate HCV infection. Thus, from the above factors, the market is expected to drive in the forecast period.

Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.

According to the National Library of Medicine, healthcare providers, social-service providers, and the general public are unaware of hepatitis b&c infections. Lack of awareness about the prevalence of chronic viral hepatitis in the U.S., as well as the appropriate methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C, most likely contributes to ongoing transmission; missed opportunities for prevention, including vaccination; missed opportunities for early diagnosis and medical care; and poor health outcomes in infected people. Thus, from the above-mentioned factors, the market is expected to get hampered in the forecast period.

Industry Analysis

The HIV/HBV/HCV test kits market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, HIV/HBV/HCV testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed HIV, HBV, and HCV during the pandemic subsequently being found to have the disease in more advanced stages. Besides, according to the World Health Organisation, in 2020, 10 countries reported disruption in Hepatitis B testing, 6 in Hepatitis C Treatment initiation, and 5 in Family Planning. In addition, as part of the original COVID-19 pandemic mitigation initiatives, in 2020, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. With this advice, patients avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Assay Based Test Kits segment is expected to hold the largest market share in HIV/HBV/HCV test kits market

The assay-based test kits segment accounted for the largest market share in 2021. The segment benefits because these are the first line of patient tests. Moreover, healthcare professionals and patients in most developing regions rely on assay-based testing results. For instance, The HCV Ag assay has the advantages of being an immunoassay, not requiring the same time-consuming and costly sample processing as molecular diagnostics, and confirming current infection. Moreover, there have been innovations in assay-based test kits. For instance, One point-of-care test that uses the GeneXpert System is the Xpert HCV Viral Load Fingerstick Test from Cepheid. The finger-stick whole blood capillaries is examined for HCV RNA as part of this point-of-care test (or assay). This type of HCV testing involves taking capillary blood from the patient through a finger prick into a collection device called a Minivette, which is then processed in a GeneXpert device at or near the point-of-care testing location.

In addition, most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), as well as many asymptomatic people in high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The existence of these HIV antibodies is frequently checked in human blood and plasma samples using enzyme-linked immunosorbent assays (ELISA). For instance, INNO-LIA HIV I/II Score is a Line Immuno Assay (LIA) that establishes the existence of antibodies against HIV-1, including group O and HIV-2 in human blood or plasma. The HIV I/II Score from INNO-LIA distinguishes between HIV-1 and HIV-2 infections. It is meant to be used in addition to an anti-HIV screening process on reactive specimens. Therefore, it has increased the demand for assay-based test kits. Thus, from the above factors, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Middle East and Africa region holds the largest market share in the global HIV/HBV/HCV test kits market

In 2021, the Middle East and Africa accounted for the highest revenue share. The increasing prevalence of HIV, innovations in the HIV/HBV/HCV test kits, advancing guidelines for self-testing and well-established infrastructure in the region are some factors the market is expected to boost in the forecast period. For instance, according to the UNAIDS, in 2020, HIV prevalence in Eswatini was 26.8 %. HIV prevalence in Eswatini increased from 22.9 % in 2001 to 26.8 % in 2020, growing at an average annual rate of 0.84%. Moreover, new WHO guidelines strongly advise offering self-testing for the hepatitis C virus (HCV) as an alternate method to HCV testing facilities. On the occasion of the International AIDS Society Conference in 2021, WHO issued the updated guidelines-it is the first for HCV self-testing. The new guidelines highlight important factors that should be taken into account by national programs, service providers, and implementers of HCV testing. These factors for HCV self-testing include developing suitable and context-specific messages, service delivery models, and support tools through community engagement; creating effective pathways for people who self-test to obtain confirmatory testing and treatment or prevention services; educating providers; creating a supportive and enabling policy environment; and using quality-assured products. Besides, WHO has also developed technical specifications for prequalifying HCV self-testing products to ensure quality. Therefore, it has increased the demand for HIV/HBV/HCV test kits. Thus, from the above factors, the Middle East and Africa region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the HIV/HBV/HCV test kits market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories Inc.; Abbott Laboratories; Meridian Bioscience, Inc.; Biopanda Reagents Ltd; Nanjing Synthgene Medical Technology Co., Ltd.; AccuBioTech Co., Ltd.; BioMerieux SA; QIAGEN; Hologic Inc; and Creative Diagnostics.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

cobas MPX: The cobas MPX Test is a multi-dye, real-time PCR multiplex test for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) for use on the cobas 6800/8800 Systems. The single assay allows for simultaneous detection of three targets, improving efficiency and accuracy.

The global HIV/HBV/HCV test kits market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.